Go Back to People
Gerald McMahon, Ph.D.
Chief Executive Officer, President and Director
Dr. McMahon joined Kolltan in 2012 as the Company’s President and Chief Executive Officer. Located adjacent to Yale Medical School, Kolltan is advancing innovative biologic products in oncology and other diseases in collaboration with the laboratory of Kolltan founder, Dr. Joseph Schlessinger. Dr. McMahon is leading the rapid advancement of the company’s R&D pipeline based on targeting receptor tyrosine kinases, with the first clinical trial program anticipated to begin in the first half of 2014.
Prior to joining Kolltan, Dr. McMahon held various roles leading private and public biotechnology companies where he was instrumental in the discovery and development of oncology products that led to approvals worldwide and generated substantial value for patients and shareholders. More recently, Dr. McMahon has been a strategic advisor to large and small companies related to their R&D pipeline including support of their financing, portfolio strategy, and business development activities.
Dr. McMahon received his B.S. in Biology and Ph.D. in Biochemistry from Rensselaer Polytechnic Institute. He has held academic appointments at the Tufts University School of Medicine, Department of Hematology & Oncology at the New England Medical Center, and the Massachusetts Institute of Technology, and he has authored over 87 publications and holds 67 issued U.S. patents.